Core Insights - The "Heart Maze Art Exhibition" in Wuhan features a special event led by Peng Kaiping, a prominent figure in positive psychology, focusing on emotional regulation techniques [1][3] - The exhibition, running from October 6 to October 10, aims to transform abstract psychological theories into immersive experiences, guiding visitors through a journey of emotional awareness and self-integration [3][4] - Peng Kaiping's "Aroma Therapy" is highlighted as a core method in the exhibition, utilizing olfactory senses to facilitate quick emotional adjustments based on neuroscience principles [3] Group 1 - The exhibition is a collaboration between JD Health, Wuhan University People's Hospital, and Wuhan Mental Health Center, emphasizing the theme of discovering one's true self beneath emotional fog [3] - The "Regulation" experience area features Peng Kaiping's therapy, which bypasses complex cognitive processes to directly evoke emotional memories [3] - Discussions at the event addressed common issues like weak social connections, with an emphasis on integrating health management and psychological adjustment into daily life [4] Group 2 - Peng Kaiping clarified misconceptions about positive psychology, stressing the need for a deeper understanding of mental health as a daily maintenance requirement, similar to physical health [4] - The exhibition combines art and science to create a tangible space for psychological well-being, allowing visitors to find personalized paths to harmonize with their emotions [4]

本次展览以"情绪聚焦疗法"为学术基底，通过"迷失—觉察—调节—释放"四重沉浸式体验环节，将深奥 的心理健康知识转化为可感知的艺术语言。"觉察区"的互动装置"情绪几何"，由中央美术学院教授费 俊、代数几何数学家许晨阳与心理学家刘正奎共同研发，通过生物信号实时生成情绪对应的几何图像， 让无形情绪具象化。"调节区"引入清华大学彭凯平教授的"闻香"疗法，观众可依据情绪状态选择匹配香 氛，体验身心舒缓的过程。整个展览以艺术为媒介，在城市公共空间中为公众构建了一个温暖、开放的 心理"缓冲带"。 本报讯 （记者袁传玺）10月6日，在世界精神卫生日到来之际，京东健康携手武汉大学人民医院、武汉 市精神卫生中心举办的"心迷艺术展"在武汉江滩正式启幕。作为京东健康在公众心理健康科普领域的一 次创新实践，本次展览跳出了传统科普的单一形式，融合艺术装置、互动科技与心理疗法，以更贴近大 众的方式传递情绪管理知识，提升社会对心理健康的认知与关注，为公众开启一场从感知情绪到接纳自 我的心灵旅程，成为心理健康科普与公益实践的深度融合，树立了创新模式的行业标杆。本次展览将持 续至10月10日。 据了解，京东互联网医院精神心理中心目前已整合全国6 ...

公司名稱: 京东健康股份有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06618 | | 說明 | | | | | | | | | 多櫃檯證券代號 | 86618 | RMB | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | | 100,000,000,000 | USD | | 0.0000005 | USD | | 50,000 | | 增加 / 減少 (-) | | | | 0 | | | | USD | | 0 | | 本月底結存 ...

智通财经APP讯，京东健康(06618)发布公告，于2025年10月1日，本公司根据首次公开发售后股份奖励 计划向承授人授出了涉及29.91万股新股份的29.91万股奖励股份，约占于授出日期已发行股份总数的 0.01%。 ...

京东健康(06618)发布公告，于2025年10月1日，本公司根据首次公开发售后股份奖励计划向承授人授出 了涉及29.91万股新股份的29.91万股奖励股份，约占于授出日期已发行股份总数的0.01%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 JD Health International Inc. 京東健康股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6618（港幣櫃台）及86618（人民幣櫃台）） 授出股份獎勵 董事會宣佈，於2025年10月1日，本公司根據首次公開發售後股份獎勵計劃向承授人授出 了涉及299,090股新股份的299,090股獎勵股份，約佔於授出日期已發行股份總數的0.01%。 授出的詳情如下： 附註：由於授出日期並非交易日，該金額為2025年9月30日（即緊接授出日期前的交易日）的收市價。 授出的理由及裨益 授出旨在通過股份所有權、股息及就股份支付的其他分派及╱或股份價值增加，使承授 人的利益與本集團的利益相一致，並鼓勵和留住承授人為本集團的長期增長和利潤作 出貢獻。 授出7,126股獎勵股份的歸屬期間少於12個月，原因為該等 股份為出於行政管理原因在一年內分批授出的部分獎勵。 表現目標： 授出並無附帶表現目 ...

曹冬 （首席執行官） 非執行董事 劉強東 （主席） 獨立非執行董事 JD Health International Inc. 京東健康股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6618（港幣櫃台）及86618（人民幣櫃台）） 董事名單及其角色和職能 京东健康股份有限公司（「本公司」）的董事會（「董事會」）成員如下。 執行董事 陳興垚 李玲 張吉豫 吳鷹 廖家傑 董事會設有三個委員會。下表詳細列出該等委員會成員。 | 董事 | 審計委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 曹冬 | | | | | （主席） 劉強東 | | | 主席 | | 陳興垚 | 主席 | 成員 | | | 李玲 | 成員 | 主席 | | | 張吉豫 | 成員 | | 成員 | | 吳鷹 | | 成員 | 成員 | | 廖家傑 | | | | 2025年9月30日 ...

Group 1 - The core point of the article is the appointment of Cao Dong as the new CEO of JD Health, following the resignation of Jin Enlin for family reasons [1] - Cao Dong has been with JD since January 2012 and has held various leadership roles within the financial system of JD Group, including CFO of JD Health from April 2019 to May 2023 [1] - The board of directors of JD Health will now include Cao Dong as the executive director, along with other members such as Liu Qiangdong and independent directors [1] Group 2 - JD Health reported a revenue of 35.29 billion RMB for the first half of 2025, representing a year-on-year increase of 24.5%, with a net profit of 3.57 billion RMB, up 35% [2] - For the full year of 2024, JD Health's revenue was 59.93 billion RMB, showing a year-on-year growth of 11.55%, while the net profit attributable to shareholders was 4.16 billion RMB, increasing by 94.31% [2] - As of the report date, JD Health's stock price rose by 1.63% to 65.55 HKD, with a total market capitalization of 209.86 billion HKD [2]

Group 1 - The first non-surgical targeted drug for treating PFIC, "Bai Er Wei" (generic name: Odevixibat capsules), has been officially launched in China, marking a significant breakthrough in the accessibility of treatment options for PFIC patients [1] - PFIC is a rare genetic disease with an incidence rate of (1-2)/100,000, typically manifesting in newborns or infants under one year old [1] - Odevixibat is the first and only approved non-surgical targeted drug for PFIC in China, which has been included in the domestic and overseas special drug directories of several provinces [1] Group 2 - JD Health's CEO, Jin Enlin, has resigned for family reasons, effective September 29, with a swift appointment of Cao Dong as the new CEO, indicating the company's efficient management response [2] - The resignation of key executives may raise short-term concerns regarding management stability, but the prompt succession plan aims to maintain market confidence [2] Group 3 - Nohui Health, known as the "first stock in cancer early screening," faces delisting risks after being suspended from trading for 18 months due to a short-selling report alleging inflated sales revenue [3] - The company's auditor, Deloitte, refused to endorse its financial statements, leading to the trading suspension, which could severely impact its future business expansion and fundraising efforts [3] Group 4 - Aimeike's subsidiary has received approval for two minoxidil topical solutions (2% and 5%) from the National Medical Products Administration, expanding its product offerings in the hair loss treatment sector [4] - The introduction of these products is expected to create new revenue growth opportunities for Aimeike and enhance its competitive position in the market [4] - This development reflects Aimeike's strength in research and product innovation, which may boost investor confidence and drive stock price appreciation [4]

Core Insights - The value of medical AI lies not just in technical parameters but in its integration into clinical scenarios to solve real problems, as stated by JD Health CEO Jin Enlin during the JD Global Technology Explorers Conference [2] - JD Health announced the upgrade of its medical model "Jingyi Qianxun 2.0" and the launch of "AI Hospital 1.0," highlighting the deep integration of AI with various industries and the importance of high-quality data [2][3] Company Developments - The Jingyi Qianxun model, launched in 2023 and upgraded to version 2.0 in June, is the first medical model capable of understanding medical reports and patient descriptions, aiming to approach human clinical cognition [3] - JD Health's AI Hospital 1.0, launched on September 25, features over a thousand expert doctor AI agents and provides comprehensive services from diagnosis to medication [3][4] - Since its independence from JD Group in 2019, JD Health has seen significant growth, with total revenue of 35.3 billion yuan in the first half of 2023, a 24.5% year-on-year increase, and a net profit of 3.57 billion yuan, up 35% [4] Industry Trends - The rapid deployment of large models in various vertical industries, including healthcare, is exemplified by JD's initiatives, which also extend to logistics, industrial, and e-commerce sectors [5] - Data quality is crucial for the success of large models, with JD focusing on enhancing data quality through rigorous selection processes and addressing challenges related to fragmented and high-privacy data in the B2B market [6] - The integration of AI in healthcare is part of a broader trend where industries are leveraging advanced models to improve efficiency and service delivery [5][6]